Updated consensus guidelines for the diagnosis and management of patients with hairy cell leukemia (HCL) and HCL-variant - PubMed
3 hours ago
- #Hairy Cell Leukemia
- #Consensus Guidelines
- #Targeted Therapy
- Updated consensus guidelines for hairy cell leukemia (HCL) and HCL-variant diagnosis and management were published.
- HCL is characterized by BRAF-V600E mutation in over 95% of cases and responds well to purine analog chemotherapy or BRAF inhibitors.
- HCL-variant lacks BRAF-V600E, typically requires combination therapy with purine analogs and rituximab, and has less durable responses.
- An international expert team updated the 2017 guidelines, summarizing current diagnostic methods and management strategies.
- The guidelines include a perspective on newer targeted therapies to improve patient outcomes.